Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor

Benzer Materyaller

• Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations
  Yazar:: Park, Sehhoon, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Pretreatment neutrophil‐lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor‐mutant non‐small cell lung cancer patients treated with tyrosine kinase inhibitors
  Yazar:: Sim, Sung Hoon, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
  Yazar:: Soomin Kim, ve diğerleri
  Baskı/Yayın Bilgisi: (2025-02-01)
• The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors
  Yazar:: Kim, Hyungjin, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer
  Yazar:: Park, Sehhoon, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)